Loring Wolcott & Coolidge Fiduciary Advisors’s Sanofi SNY Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10	Closed	-$530	–	557
2025 Q1	$530	Hold	10	–	–	﹤0.01%	545
2024 Q4	$533	Hold	10	–	–	﹤0.01%	546
2024 Q3	$521	Buy	+10	New	+$540	﹤0.01%	562
2024 Q1	–	Sell	-151	Closed	-$7.54K	–	588
2023 Q4	$7.54K	Hold	151	–	–	﹤0.01%	506
2023 Q3	$7.02K	Hold	151	–	–	﹤0.01%	532
2023 Q2	$8.14K	Buy	+151	New	+$8.13K	﹤0.01%	551
2022 Q3	–	Sell	-200	Closed	-$10K	–	634
2022 Q2	$10K	Buy	+200	New	+$10.6K	﹤0.01%	544
2021 Q1	–	Sell	-325	Closed	-$16K	–	639
2020 Q4	$16K	Buy	+325	New	+$16K	﹤0.01%	530
2019 Q4	–	Sell	-808	Closed	-$37K	–	713
2019 Q3	$37K	Buy	+808	New	+$34.8K	﹤0.01%	441
2017 Q4	–	Sell	-78	Closed	-$4K	–	862
2017 Q3	$4K	Hold	78	–	–	﹤0.01%	611
2017 Q2	$4K	Buy	+78	New	+$3.73K	﹤0.01%	600

Other funds holding SNY

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's SNY Position: Q2 2025 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Sanofi (SNY) in Q2 2025, closing a stake of 10 shares — an estimated $530 sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in SNY in Q2 2017 and held it in 11 quarters. The position peaked at $37K in Q3 2019. 731 funds tracked by Wall St. Rank hold SNY as of Q2 2025.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Sanofi position as of Q2 2025 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 10 Sanofi shares in Q2 2025, an estimated $530.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Sanofi in Q2 2017 and held it in 11 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Sanofi position peaked at $37K in Q3 2019.
731 funds tracked by Wall St. Rank held Sanofi as of Q2 2025.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.